secwatch.observer — SEC 8-K summary
======================================

Issuer:     Vyome Holdings, Inc (HIND)
CIK:        0001427570
Form:       8-K
Filed at:   2025-08-19T23:59:59+00:00
Accession:  0001213900-25-078603
Event type: m_and_a
Sentiment:  neutral
Materiality: 0.85
Item codes: 2.01, 3.02, 3.03, 5.02, 5.03, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Vyome Holdings (HIND) completes merger and asset sale, appoints new CEO and board
--------------------------------------------------------------------------------

- Merger closed: Vyome Therapeutics becomes subsidiary; company renamed Vyome Holdings, Inc.
- Asset sale: ReShape sold its assets to Biorad for $2.25M cash, assuming substantially all liabilities.
- Reverse stock split: 1-for-4 split effective Aug 15, 2025 to meet Nasdaq minimum bid price.
- Leadership: New CEO Venkateswarlu Nelabhotla, interim CFO Robert Dickey; six new directors appointed.
- Equity sale: 529,137 shares sold at $11.02 per share in unregistered offering post-merger.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1427570/000121390025078603/0001213900-25-078603-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1427570/000121390025078603/ea0253813-8k_vyome.htm
  HTML page:      https://secwatch.observer/filing/0001213900-25-078603

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer